N-Power Medicine has achieved a significant milestone by raising $32 million in a Series B financing round. This crucial funding will facilitate the expansion of its community oncology network, enhance pharmaceutical partnerships, and foster the ongoing development of innovative products designed to improve cancer care.
Strategic Investment
The Labcorp Venture Fund has come on board as a new strategic investor, contributing essential expertise and resources to N-Power. Alongside Labcorp, existing investors such as the Merck Global Health Innovation Fund and Innovatus Capital Partners have also participated, along with a U.S.-based biotech investor. This collective backing reflects a growing confidence in N-Power’s mission and its groundbreaking technological advancements.
Innovative Technology
At the heart of N-Power’s innovation is the Prospective External Control Arm (ProECA) platform. This state-of-the-art technology enables the creation of prospective, trial-grade external control arms derived from routine cancer care data. By utilizing everyday clinical practices, ProECA aims to minimize reliance on conventional randomized control arms in clinical trials. This transformation not only simplifies the patient enrollment process but also significantly reduces clinical trial durations and lowers drug development costs.
Current Operations
N-Power’s first ProECA is focused on non-small cell lung cancer (NSCLC) and is currently operational at over 40 community oncology sites. This initiative has garnered interest from various pharmaceutical and biotech companies, which are leveraging the platform for early development programs and Phase 4 initiatives. This enhances their research capabilities and accelerates the time-to-market for new treatments.
Future Aspirations
Looking forward, N-Power has ambitious plans to launch additional ProECA programs targeting colorectal cancer and prostate cancer, with a projected rollout in late 2026. These initiatives are anticipated to further amplify N-Power’s impact on oncology research and improve patient outcomes, showcasing the company’s dedication to advancing cancer care through innovative methodologies.
Industry Perspectives
Megann Vaughn Watters, Managing Director of Labcorp Venture Fund, acknowledged the potential of N-Power’s innovative approach to expedite oncology drug development while broadening access to clinical research in community care settings. Mark Lee, M.D., Ph.D., Co-Founder and CEO of N-Power Medicine, expressed that with Labcorp’s involvement, this financing will enable them to scale operations and establish a new standard for oncology drug development.
In summary, N-Power Medicine’s successful financing round marks a pivotal moment in its mission to transform oncology research and patient care. With the introduction of its ProECA platform and upcoming initiatives, the company is poised to make a lasting impact in the field of oncology.
- N-Power Medicine raised $32 million in Series B funding.
- The ProECA platform innovates cancer clinical trials using real-world data.
- Future projects will target colorectal and prostate cancers by late 2026.
- Labcorp Venture Fund joins existing investors to support N-Power’s growth.
This funding underscores a commitment to improving cancer treatment accessibility and efficiency.
Read more → pulse2.com